Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous injection and Perjeta as an intravenous infusion, says the CHMP. According to the ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

The new antibody-drug conjugate reduced the risk of disease progression or death by 37%.

Participants were randomly assigned to receive an infusion of zoledronate at a dose of 5 mg at baseline and at 5 years (zoledronate–zoledronate group), zoledronate at a dose of 5 mg at baseline ...

1 Findings for fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu ... Janjigian noted that the incidences of immune-mediate adverse effects and infusion reactions were as expected. 1,7 Several ...

For example, trastuzumab (Herceptin) is a monoclonal antibody that targets HER2-positive breast ... They are typically administered through intravenous infusion ICIs are often used in combination with ...

When the drug enters the blood stream, by IV infusion, the antibodies deliver the anti-cancer drug directly to the ... This excitement stems from the fact that HER2-low breast cancers are targetable ...

1 Department of Pharmaceutics, Rutgers University, Piscataway, NJ, United States 2 Cancer Pharmacology Program, Cancer Institute of New Jersey, New Brunswick, NJ, United States This review article ...

DATROWAY was administered by intravenous infusion once every three weeks ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca ...